Breve descripción
El estudio está evaluando la seguridad y eficacia de un inhibidor de C3 dirigido en investigación llamado pegcetacoplan en adultos que tienen recurrencia de C3G o IC-MPGN después de un trasplante de riñón.
Médico del ensayo / Coordinador del estudio
Elizabeth Carfioli
Estimated Enrollment
12 pacientes
Estimated End Date
Fin de inscripción – diciembre de 2021; Fin de estudio – Septiembre 2022
Trial is for people with
Diagnosis of C3G or IC-MPGN that has recurred after a kidney transplant. In addition, participants must be: - at least 18 years of ...
Study Goal
The NOBLE study is exploring whether pegcetacoplan has an effect on the build up of the complement protein C3 in the kidney, that ...
What is involved for the patient?
After completing a screening period, study participants will be randomly assigned (randomized) to one of two treatment ...
About the drug or intervention
Pegcetacoplan is an investigational, targeted C3 inhibitor. It is administered via a needle, under the skin (subcutaneous), twice ...